Kebir, Sied ; Schaub, Christina ; Junold, Nina ; Hattingen, Elke 
; Schäfer, Niklas ; Steinbach, Joachim P. ; Weyerbrock, Astrid ; Hau, Peter ; Goldbrunner, Roland ; Galldiks, Norbert ; Weller, Johannes ; Mack, Frederic ; Tzaridis, Theophilos ; Bähr, Oliver ; Seidel, Clemens ; Schlegel, Uwe ; Schmidt-Graf, Friederike ; Rohde, Veit ; Borchers, Christian ; Tabatabai, Ghazaleh ; Hänel, Mathias ; Sabel, Michael ; Gerlach, Rüdiger ; Krex, Dietmar ; Belka, Claus ; Vatter, Hartmut ; Proescholdt, Martin ; Glas, Martin ; Herrlinger, Ulrich
; Schäfer, Niklas ; Steinbach, Joachim P. ; Weyerbrock, Astrid ; Hau, Peter ; Goldbrunner, Roland ; Galldiks, Norbert ; Weller, Johannes ; Mack, Frederic ; Tzaridis, Theophilos ; Bähr, Oliver ; Seidel, Clemens ; Schlegel, Uwe ; Schmidt-Graf, Friederike ; Rohde, Veit ; Borchers, Christian ; Tabatabai, Ghazaleh ; Hänel, Mathias ; Sabel, Michael ; Gerlach, Rüdiger ; Krex, Dietmar ; Belka, Claus ; Vatter, Hartmut ; Proescholdt, Martin ; Glas, Martin ; Herrlinger, Ulrich 
Abstract
Purpose The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment ...
Owner only: item control page
Altmetric